Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapy.
Shu R, Hammett M, Evtimov V, Pupovac A, Nguyen NY, Islam R, Zhuang J, Lee S, Kang TH, Lee K, Nisbet I, Hudson P, Lee JY, Boyd R, Trounson A.
Shu R, et al. Among authors: lee k, lee jy, lee s.
Bioeng Transl Med. 2023 Jul 10;8(6):e10571. doi: 10.1002/btm2.10571. eCollection 2023 Nov.
Bioeng Transl Med. 2023.
PMID: 38023726
Free PMC article.